Robert W. Baird Raises Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price boosted by Robert W. Baird from $52.00 to $62.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other equities research analysts also recently weighed in on CRNX. Morgan Stanley upped […]

Related Keywords

Marc Wilson ,Stephenf Betz ,Robertw Baird ,Insider Transactions At Crinetics Pharmaceuticals ,News Ratings For Crinetics Pharmaceuticals Daily ,Cantor Fitzgerald ,Morgan Stanley ,Crinetics Pharmaceuticals Inc ,Crinetics Pharmaceuticals Stock Down ,Crinetics Pharmaceuticals ,Securities Exchange Commission ,Highmark Wealth Management ,Crinetics Pharmaceuticals Company Profile ,Comerica Bank ,Institutional Investors Weigh In On Crinetics Pharmaceuticals ,Analyst Recommendations For Crinetics Pharmaceuticals ,Free Report ,Moderate Buy ,Pharmaceuticals Stock Down ,Get Free Report ,Exchange Commission ,Mark Wealth Management ,Amalgamated Bank ,Crinetics Pharmaceuticals Daily ,